Summary
This is a Phase 1, open-label, dose-escalation trial of avelumab [antibody targeting
programmed death ligand 1 (anti PD-L1)] with consecutive parallel group expansion in
participants with selected tumor indications. New recruitment is open for all active cohorts.
Active cohorts: Escalation revised dosing regimen cohort.
Closed cohorts: Non-small cell lung cancer (NSCLC, first line), NSCLC (post-platinum),
metastatic breast cancer (MBC), colorectal cancer (CRC), urothelial carcinoma (secondary),
mesothelioma, gastric/GEJ cancer (first line switch maintenance and second line), and ovarian
cancer (secondary and platinum refractory + liposomal doxorubicin), renal cell carcinoma
(second line) melanoma and head, neck squamous cell carcinoma (HNSCC), castrate-resistant
prostate cancer (CRPC), adrenocortical carcinoma (ACC) urothelial carcinoma (efficacy),
gastric/gastroesophageal junction (GEJ) cancer (third line), renal cell carcinoma (RCC, first
line) and escalation phase .